Corrected: Entrada raises $100M for Duchenne development; eFFECTOR winds down

Plus, news about NeuroBo, Vico Therapeutics, Takeda, Checkpoint Therapeutics, CombiGene, Spark Therapeutics, ANI, Alimera Sciences and OSE Immunotherapeutics:

Entrada Therapeutics raises $100M from stock sale …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients – Biotech Investments

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly

May 14, 2024

Generative AI in Healthcare Survey Reveals Rising Adoption Amidst Challenges

What You Should Know: – John Snow Labs, the AI for healthcare company announced the findings of the inaugural Generative AI in Healthcare Survey. Conducted

April 24, 2024

Why long Covid might predate the pandemic

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for

October 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.